Coronavirus Essential podcast | Covaxin phase 3 trials efficacy at 81%, says Bharat Biotech; France looking to secure the Indian vaccine
Tune in to the Coronavirus Essential podcast for all the latest updates on the pandemic.
March 03, 2021 / 06:47 PM IST
On March 3, Bharat Biotech said that its Covaxin vaccine was 81 percent effective in preventing COVID-19 after a third round of clinicals trials.
Meanwhile, France could become the second country after Brazil to purchase doses of Covaxin as the country grapples with a daunting vaccination challenge and rising number of infections.Tune in to the Coronavirus Essential podcast with Shraddha Sharma for more.